Bringing together community stakeholders and healthcare leaders can diminish health inequities, said Shantanu Agrawal, MD, MPhil, CEO and president of National Quality Forum.
Bringing together community stakeholders and healthcare leaders can diminish health inequities, said Shantanu Agrawal, MD, MPhil, CEO and president of National Quality Forum.
Transcript
Addressing social determinants of healthcan be a daunting task for a health system. Are there any recommendations for how to start delving into this area?
I think if the health system is really thinking of getting into this area, first and foremost, prioritize it and make that transparent within the health system. I think this is a conversation about values and priorities that health systems should be having that they need to have. I think once it’s clear that that’s a goal—and hopefully it is for everybody—then it’s really about reaching out to communities and thinking through the diversity of stakeholders that will be needed to address disparities of interest.
So, like most things in healthcare you can’t take a bull to the ocean approach you need to think of the 1, 2, or 3 areas of greatest need for your population. That may be food and security, it may be homelessness or housing insecurity. But, I think prioritizing upfront working with the relevant community stakeholders to what the focus areas will be is really critical. Then it’s harnessing all the available resources to actually make progress.
I think one of the both challenges but also building blocks of this kind of approach is a lot of our social programs are highly fragmented from each other. I think even the act of bringing communities leaders together with the healthcare leadership, pooling those resources that can have a really positive impact on itself. We’ve seen as we look across the country to communities and delivery systems that are doing this work we look we’ve seen just by making this a priority, by working with the community, by surfacing good ideas, and then pooling resources, we’ve literally seen that have a tremendous impact on patients. It is imminently doable, it just has to be a value that the communities and delivery systems focus on and want to see improvement on.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
2 Commerce Drive
Cranbury, NJ 08512